EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment outcome comparisons of first‐line targeted therapy in patients with KRAS wild‐type metastatic colorectal cancer: A nationwide database study

Yi-Hsin Liang iD, Kuo-Hsing Chen, Yu-Yun Shao iD

Cancer Medicine · 2023

DOI: 10.1002/cam4.6196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Yi-Hsin Liang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institutes of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Antineoplastic Agents, Rectal Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, National Taiwan University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The first‐line systemic therapy for metastatic colorectal cancer (mCRC) is a combination of one targeted therapy agent and a chemotherapy doublet. Whether bevacizumab or anti‐epidermal growth factor receptor (anti‐EGFR) monoclonal antibody (mAb) is the more effective addition to a chemotherapy doublet as the first‐line treatment for inoperable KRAS wild‐type mCRC remains controversial in prior clinical trials. Moreover, the association between the sidedness of primary tumors and the efficacy of anti‐EGFR mAb needs to be addressed.

Methods

We established a cohort of patients with KRAS wild‐type mCRC who were treated with first‐line targeted therapy plus doublet chemotherapy between 2013 and 2018 using Taiwan's National Health Insurance Research Database. Secondary surgery was defined as either resection of primary tumors, liver metastases, lung metastases, or radiofrequency ablation.

Results

A total of 6482 patients were included; bevacizumab and anti‐EGFR mAb were the first‐line targeted therapies in 3334 (51.4%) and 3148 (48.6%) patients, respectively. Compared with those who received bevacizumab, patients who received anti‐EGFR mAb exhibited significantly longer overall survival (OS; median, 23.1 vs. 20.2 months, p = 0.012) and time to treatment failure (TTF; median, 11.3 vs. 10 months, p < 0.001). Among left‐sided primary tumors, the OS and TTF benefits of anti‐EGFR mAb remained. Among right‐sided primary tumors, the OS and TTF were similar regardless of the type of targeted therapy. In multivariate analyses, first‐line anti‐EGFR mAb therapy remained an independent predictor of longer OS and TTF for left‐sided primary tumors. Patients who received anti‐EGFR mAb were more likely to receive secondary surgery (29.6% vs. 22.6%, p < 0.0001) than patients who received bevacizumab.

Conclusion

For patients who received first‐line doublet chemotherapy for KRAS wild‐type mCRC, adding anti‐EGFR mAb was associated with significantly longer OS and TTF, especially for left‐sided primary tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColonic NeoplasmsAntineoplastic AgentsRectal NeoplasmsHumansBevacizumabProto-Oncogene Proteins p21(ras)Antibodies, MonoclonalTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsCetuximab

Stichwörter der Autor:innen

EGFRbevacizumabcetuximabmetastatic colorectal cancerpanitumumabsecondary surgery

Substanzen

BevacizumabProto-Oncogene Proteins p21(ras)Antibodies, MonoclonalAntineoplastic AgentsCetuximabKRAS protein, human

Autor:innen und Institutionen

  • Graduate Institutes of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Center of Genomic and Precision Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.

ORCID-Profile: Yi-Hsin Liang, Yu-Yun Shao

Förderung

  • Ministry of Science and Technology, Taiwan
  • National Taiwan University Hospital

Zitieren

APA

Liang, Y. H., Chen, K. H., & Shao, Y. Y. (2023). Treatment outcome comparisons of first‐line targeted therapy in patients with KRAS wild‐type metastatic colorectal cancer: A nationwide database study. Cancer Medicine. https://doi.org/10.1002/cam4.6196

Vancouver

Liang YH, Chen KH, Shao YY. Treatment outcome comparisons of first‐line targeted therapy in patients with KRAS wild‐type metastatic colorectal cancer: A nationwide database study. Cancer Medicine. 2023. doi:10.1002/cam4.6196

BibTeX
@article{Liang2023,
  author = {Liang, Yi-Hsin and Chen, Kuo-Hsing and Shao, Yu-Yun},
  title = {Treatment outcome comparisons of first‐line targeted therapy in patients with KRAS wild‐type metastatic colorectal cancer: A nationwide database study},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6196}
}
Kostenlos starten →